Treatment of hypertension in the elderly

Geriatrics

Volumn 63, Issue 10, 2008, Pages 21-25

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Alpha blockers; Anglotensin receptor blockers; Anglotensin converting enzyme inhibitors; Antihypertensive drugs; Beta blockers; Calcium channel blockers; Centrally acting antihypertenslves; Direct vasodilators; Diuretics; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; MINOXIDIL; NIFEDIPINE; NITRATE; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; RAMIPRIL; TELMISARTAN; VASODILATOR AGENT; VERAPAMIL;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE MONITORING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONGESTIVE HEART FAILURE; COUGHING; DEPRESSION; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG WITHDRAWAL; ELDERLY CARE; FALLING; FLUID RETENTION; FOLLOW UP; GASTROENTERITIS; HEADACHE; HEART FAILURE; HEART INFARCTION; HIRSUTISM; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LUPUS LIKE SYNDROME; ORTHOSTATIC HYPOTENSION; PERICARDIAL EFFUSION; POSTPRANDIAL HYPOTENSION; RASH; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINUS ARREST; SINUS NODE; STROKE; SYNCOPE; TACHYCARDIA; TASTE DISORDER; UREMIA; VASCULAR RESISTANCE; VEIN DILATATION; AGED; DRUG COMBINATION; REVIEW;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 54049138820     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol: Med Sci. 2002;57A:M45-M46.
2. Mendelson G, Ness J, Aronow WS. Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47:597-599.
3. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.
4. Aronow WS, Ahn C. Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol. 1996;77:864-866.
5. Aronow WS, Ahn C, Gutstein H. Risk factors for new atherothrombotic brain infarction in 664 older men and 1488 older women. Am J Cardiol. 1996;77:1381-1383.
6. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999;84:611-612.
7. Stokes J III, Kannel WB, Wolf PA, et al. The relative importance of selected risk factors for various manifestations of cardiovasclar disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation. 1987;75(suppl V):V-65-V-73.
8. Ness J, Aronow WS, Ahn C. Risk factors for peripheral arterial disease in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48:312-314.
9. Aronow WS, Frishman WH. Effect of antihypertensive drug treatment on cognitive function. Clin Geriatr. 2006;14(11):25-28.
10. Chobanian AV, Bakris GL, Black HR. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC VII Report. JAMA. 2003;289:2560-2572.
11. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
12. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
13. Beckett NS, Peters R. Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Eng J Med. 2008; 358:1887-1898.
14. Aronow WS, Frishman WH. Treatment of hypertension and prevention of ischemic stroke. Current Cardiology Reports 2004; 6:124-129.
15. Aronow WS. Older age should not be a barrier to the treatment of hypertension. Nat Clin Pract Cardiovasc Med. 2008;5(9):514-515.
16. Koka M, Joseph J, Aronow WS. Adequacy of control of hypertension in an academic nursing home. J Am Med Dir Assoc. 2007; 8:538-540.
17. Mendelson G, Nassimiha D, Aronow WS. Simultaneous measurements of blood pressures in right and left brachial arteries. Cardiol in Review. 2004;12:276-278.
18. Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension: current diagnosis and treatment. International J Cardiol. 2008; 124:6-21.
19. Aronow WS. Dizziness and syncope. In: Hazzard WR, Blass JP, Ettinger WH Jr, Halter JB, Ouslander JG, eds. Principles of Geriatric Medicine and Gerontology, 4th edition New York City: McGraw-Hill, Inc, 1998, 1519-1534.
20. Gribbin B, Pickering GT, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res. 1971;29:424-431.
21. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA. 2001;285:2719-2728.
22. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358: 1547-1559.
23. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347:1256-1261.
24. Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin-converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med. 1991;115:513-519.
25. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.
26. Pahor M, Guralnik JM, Corti C, et al. Longterm survival and use of antihypertensive medications in older persons. J Am Geriatr Soc. 1995;43:1191-1197.
27. Aronow WS. Verapamil as an antiarrhythmic agent. In Drug Treatment of Cardiac Arrhythmias. Gould LA (ed): Futura Publishing Company, Inc., Mount Kisco, New York, 1983, pp 325-341.
28. The Multicenter Diltiazern Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
29. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1961.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
31. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol. 2002;89:1207-1209
32. Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In Aronow WS, Reg JL, Rich MW (eds): Cardiovascular Disease in the Elderly, fourth edition, New York City, Informa Healthcare, 2008, pp 99-135.
33. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100:1016-1030.
34. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
35. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol. 2001;88:1298-1300.
36. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1994;74:674-680.
37. Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol. 1994;74:267-270.
38. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HP). Lancet. 1999;353:2001-2007.
39. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting- enzyme inhibitors. Am J Cardiol. 1997;80:207-209.
40. Aronow WS, Frishman WH. Angina in the elderly. In: Aronow WS, Fleg JL, Rich MW, eds. Cardiovascular Disease in the Elderly, fourth edition. New York City: Informa Healthcare, 2008, pp. 269-292.
41. Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol. 1994;74:613-615.
42. Aronow WS. Treatment of atrial fibrillation. Part 1. Cardiology in Review. 2008;16:181-188.
43. Aronow WS. The heart and thyroid disease. In: Gambert SR, ed. Clinics in Geriatric Medicine. Thyroid Disease. Philadelphia: W. B. Saunders Co, 1995, pp. 219-229.
44. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the International Society for Heart and Lung Transplantation. Endorsed by the Heart Failure Society of America. J Am Coll Cardiol. 2001;38:2101-2113.
45. Progress Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
46. Smith SC Jr, Allen J, Blair SN, et al. ACC/AHA guidelines for secondary prevention for patients with coronary and other athero-sclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113: 2363-2372.
47. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
48. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26 (supplement 1):533-550.